248 related articles for article (PubMed ID: 32373615)
1. The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases.
Cadamuro M; Girardi N; Gores GJ; Strazzabosco M; Fabris L
Front Med (Lausanne); 2020; 7():115. PubMed ID: 32373615
[TBL] [Abstract][Full Text] [Related]
2. Emerging concepts in biliary repair and fibrosis.
Fabris L; Spirli C; Cadamuro M; Fiorotto R; Strazzabosco M
Am J Physiol Gastrointest Liver Physiol; 2017 Aug; 313(2):G102-G116. PubMed ID: 28526690
[TBL] [Abstract][Full Text] [Related]
3. Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target.
Trussoni CE; O'Hara SP; LaRusso NF
Semin Immunopathol; 2022 Jul; 44(4):527-544. PubMed ID: 35178659
[TBL] [Abstract][Full Text] [Related]
4. Macrophages in cholangiopathies.
Bruneau A; Guillot A; Tacke F
Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2
Zhou T; Kyritsi K; Wu N; Francis H; Yang Z; Chen L; O'Brien A; Kennedy L; Ceci L; Meadows V; Kusumanchi P; Wu C; Baiocchi L; Skill NJ; Saxena R; Sybenga A; Xie L; Liangpunsakul S; Meng F; Alpini G; Glaser S
EBioMedicine; 2019 Oct; 48():130-142. PubMed ID: 31522982
[TBL] [Abstract][Full Text] [Related]
6. Cellular senescence in the cholangiopathies.
Bogert PS; O'Hara SP; LaRusso NF
Curr Opin Gastroenterol; 2022 Mar; 38(2):121-127. PubMed ID: 35098933
[TBL] [Abstract][Full Text] [Related]
7. The Cholangiopathies.
Lazaridis KN; LaRusso NF
Mayo Clin Proc; 2015 Jun; 90(6):791-800. PubMed ID: 25957621
[TBL] [Abstract][Full Text] [Related]
8. Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the "Reactive" Biliary Epithelial Phenotype.
Fabris L; Brivio S; Cadamuro M; Strazzabosco M
Stem Cells Int; 2016; 2016():2953727. PubMed ID: 26880950
[TBL] [Abstract][Full Text] [Related]
9. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.
Fabris L; Fiorotto R; Spirli C; Cadamuro M; Mariotti V; Perugorria MJ; Banales JM; Strazzabosco M
Nat Rev Gastroenterol Hepatol; 2019 Aug; 16(8):497-511. PubMed ID: 31165788
[TBL] [Abstract][Full Text] [Related]
10. Bile Acids and Biliary Fibrosis.
Aseem SO; Hylemon PB; Zhou H
Cells; 2023 Mar; 12(5):. PubMed ID: 36899928
[TBL] [Abstract][Full Text] [Related]
11. Animal models of cholestasis: An update on inflammatory cholangiopathies.
Mariotti V; Cadamuro M; Spirli C; Fiorotto R; Strazzabosco M; Fabris L
Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):954-964. PubMed ID: 30398152
[TBL] [Abstract][Full Text] [Related]
12. The crucial role of cholangiocytes in cholangiopathies.
Park SM
Gut Liver; 2012 Jul; 6(3):295-304. PubMed ID: 22844556
[TBL] [Abstract][Full Text] [Related]
13. Involvement of cholangiocyte proliferation in biliary fibrosis.
Priester S; Wise C; Glaser SS
World J Gastrointest Pathophysiol; 2010 Jun; 1(2):30-7. PubMed ID: 21607140
[TBL] [Abstract][Full Text] [Related]
14. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
Pollheimer MJ; Racedo S; Mikels-Vigdal A; Marshall D; Bowlus C; Lackner C; Madl T; Karlsen TH; Hov JR; Lyman SK; Adamkewicz J; Smith V; Moreau E; Zollner G; Eide TJ; Stojakovic T; Scharnagl H; Gruber HJ; Stauber RE; Trauner M; Fickert P
J Hepatol; 2018 Aug; 69(2):368-377. PubMed ID: 29709678
[TBL] [Abstract][Full Text] [Related]
15. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis.
Pollheimer MJ; Fickert P; Stieger B
Mol Aspects Med; 2014 Jun; 37():35-56. PubMed ID: 24141039
[TBL] [Abstract][Full Text] [Related]
16. Cellular Interactions and Crosstalk Facilitating Biliary Fibrosis in Cholestasis.
Ceci L; Gaudio E; Kennedy L
Cell Mol Gastroenterol Hepatol; 2024; 17(4):553-565. PubMed ID: 38216052
[TBL] [Abstract][Full Text] [Related]
17. Functional and structural features of cholangiocytes in health and disease.
Maroni L; Haibo B; Ray D; Zhou T; Wan Y; Meng F; Marzioni M; Alpini G
Cell Mol Gastroenterol Hepatol; 2015 Jul; 1(4):368-380. PubMed ID: 26273695
[TBL] [Abstract][Full Text] [Related]
18. [Inflammatory and neoplastic cholangiopathies.].
Alvaro D; Bragazzi MC; Ridola L
Recenti Prog Med; 2018 Dec; 109(12):595-599. PubMed ID: 30667389
[TBL] [Abstract][Full Text] [Related]
19. Cholangiocyte death in ductopenic cholestatic cholangiopathies: Mechanistic basis and emerging therapeutic strategies.
Salas-Silva S; Simoni-Nieves A; Lopez-Ramirez J; Bucio L; Gómez-Quiroz LE; Gutiérrez-Ruiz MC; Roma MG
Life Sci; 2019 Feb; 218():324-339. PubMed ID: 30610870
[TBL] [Abstract][Full Text] [Related]
20. Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets.
Sato K; Glaser S; Kennedy L; Liangpunsakul S; Meng F; Francis H; Alpini G
Expert Opin Ther Targets; 2019 Jun; 23(6):461-472. PubMed ID: 30990740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
